Large gap with delayed quotes
|
Last quote
04/27/2026
-
19:22:20
|
Bid
04/27/2026 -
19:25:07
|
Bid Volume |
Ask
04/27/2026 -
19:25:07
|
Ask Volume |
|---|---|---|---|---|
|
570.63
+3.47
(
+0.61% )
|
569.37
|
80 |
571.74
|
40 |
Analysis date: 24.04.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 31.03.2026.
Interest
Strong
Strong
Three stars since 24.04.2026.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 24.02.2026 at a price of 473.43.
Evaluation
Neutral
Neutral
Based on its growth potential and our own criteria, we believe the share price is currently fairly priced.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 27.02.2026.
4wk Rel Perf
-2.64%
-2.64%
The four-week dividend-adjusted underperformance versus SP500 is 2.64%.
Sensibility
Middle
Middle
The stock has been on the moderate-sensitivity level since 30.09.2025.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -1.58%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.00%.
Mkt Cap in $bn
24.86
24.86
With a market capitalization >$8bn, UNITED THERAPEUTICS is considered a large-cap stock.
G/PE Ratio
1.08
1.08
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of
LT P/E
11.79
11.79
The estimated PE is for the year 2029.
LT Growth
12.73%
12.73%
The annualized growth estimate is for the current year to 2029.
Avg. Nb analysts
9
9
Over the last seven weeks, an average of 9 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
39
39
For 1% of index variation, the stock varies on average by 0.39%.
Correlation
0.09
0.09
Stock movements are totally independent of index variations.
Value at Risk
136.12
136.12
The value at risk is estimated at USD 136.12. The risk is therefore 24.00%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
08.06.2005
08.06.2005